Italy fines Roche and Novartis

Share this article:

Italy's health ministry has fined Roche and Novartis $1.6 billion for the way in which the two Swiss companies marketed the eye drug Lucentis. The Wall Street Journal reports that the fine comes after a government anti-trust division found the companies “colluded to push doctors toward their jointly marketed Lucentis treatment,” by creating what the WSJ describes as “an artificial distinction between the two products...presenting Avastin as being riskier than Lucentis, in an effort to influence prescriptions.”

The $1.6 billion is for damages the government says covers 2012 to 2014. Novartis and Roche told the WSJ they will appeal the decision.

Roche subsidiary Genentech has also been criticized for its efforts to prod Lucentis prescriptions over those for cheaper Avastin. As the Washington Post reported in December, efforts to discourage doctors from using Avastin in place of Lucentis include marketing tactics, such as packaging the lower-priced medication in difficult-to-break-up quantities and not seeking an official expansion of Avastin's indication, keeping it from officially competing against Lucentis among wet-AMD patients.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.